Well, one
of the best anticancer drugs is
no more IP protected. I personally worked with this drug – excellent chemical,
physical, pharmacological properties. I wish it would be more this type of drug
on the market. Now it is available for everybody!
"Taxotere, the successor to the cancer drug Taxol, generated 922 million euros ($1.2 billion) last year for Paris-based Sanofi. That’s a 57 percent drop from the year before because of generic-drug competition, Sanofi said"
No comments:
Post a Comment